Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 5/2011

01.10.2011

LOX-1, Oxidative Stress and Inflammation: A Novel Mechanism for Diabetic Cardiovascular Complications

verfasst von: Meiling Yan, Jawahar L. Mehta, Weifang Zhang, Changping Hu

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Diabetes mellitus is a common metabolic disease characterized by a state of oxidative stress, inflammation and endothelial dysfunction. This malady can lead to a number of complications such as ischemic heart disease, nephropathy, neuropathy, retinopathy and impaired wound healing. The etiology of diabetic complications is multifactorial, and is closely associated with oxidative stress and inflammation. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a receptor for oxidized low density lipoprotein (ox-LDL), plays critical roles in multiple signal transduction pathways and is involved in the process of oxidative stress and inflammation. Recent studies provide important insights into the roles of LOX-1 in the development and progression of diabetic vasculopathy which is the underlying mechanism of diabetic complications. In this review, we summarize mechanistic studies, mainly related to LOX-1, on the development and progression of diabetes mellitus and its cardiovascular complications.
Literatur
1.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.PubMedCrossRef
2.
3.
Graves DT, Kayal RA. Diabetic complications and dysregulated innate immunity. Front Biosci. 2008;13:1227–39.PubMedCrossRef
4.
Mazzone T, Chait A, Plutzky J. Addressing cardiovascular disease risk in diabetes: insights from mechanistic studies. Lancet. 2008;371:1800–9.PubMedCrossRef
5.
Karalliedde J, Gnudi L. Future strategies to prevent renal microvascular disease complications in diabetes. Future Cardiol. 2008;4:77–83.PubMedCrossRef
6.
Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73–7.PubMedCrossRef
7.
Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J. 1998;334:9–13.PubMed
8.
Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K, et al. Oxidized LDL modulates Bax/Bcl-2 through the lectin-like ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:955–60.PubMedCrossRef
9.
Martín-Fuentes P, Civeira F, Recalde D, García-Otín AL, Jarauta E, Marzo I, et al. Individual variation of scavenger receptor expression in human macrophages with oxidized low-density lipoprotein is associated with a differential inflammatory response. J Immunol. 2007;179:3242–8.PubMed
10.
Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002;277:49982–8.PubMedCrossRef
11.
Hu CP, Mehta JL. Biology of LOX-1 in relation to atherogenesis. Future lipidol. 2008;3:689–96.CrossRef
12.
Ogura S, Kakino A, Sato Y, Fujita Y, Iwamoto S, Otsui K, et al. LOX-1: The multifunctional receptor underlying cardiovascular dysfunction. Circ J. 2009;73:1993–9.PubMedCrossRef
13.
Nagase M, Hirose S, Sawamura T, Masaki T, Fujita T. Enhanced expression of endothelial oxidized low-density lipoprotein receptor (LOX-1) in hypertensive rats. Biochem Biophys Res Commun. 1997;237:496–8.PubMedCrossRef
14.
Chen M, Nagase M, Fujita T, Narumiya S, Masaki T, Sawamura T. Diabetes Enhances Lectin-like Oxidized LDL Receptor-1 (LOX-1) Expression in the Vascular Endothelium: Possible Role of LOX-1 Ligand and AGE. Biochem Biophys Res Commun. 2001;287:962–8.PubMedCrossRef
15.
Chen H, Li D, Sawamura T, Inoue K, Mehta J. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: Modulation by losartan. Biochem Biophys Res Commun. 2000;276:1100–4.PubMedCrossRef
16.
Ueno T, Kaname S, Takaichi K, Nagase M, Tojo A, Onozato ML, et al. LOX-1, an oxidized low-density lipoprotein receptor, was upregulated in the kidneys of chronic renal failure rats. Hypertens Res. 2003;26:117–22.PubMedCrossRef
17.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–81.PubMedCrossRef
18.
Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463–524.PubMedCrossRef
19.
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.PubMedCrossRef
20.
Rudijanto A. The expression and down stream effect of lectin like-oxidized low Density lipoprotein 1 (LOX-1) in hyperglycemic state. Acta Med Indones. 2007;39:36–43.PubMed
21.
Hayden JM, Reaven PD. Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors. Curr Opin Lipidol. 2000;11:519–28.PubMedCrossRef
22.
McSorley PT, Young IS, McEneny J, Fee H, McCance DR. Susceptibility of low-density lipoprotein to oxidation and circulating cell adhesion molecules in young healthy adult offspring of parents with type 2 diabetes. Metabolism. 2004;53:755–9.PubMedCrossRef
23.
Hussein OA, Gefen Y, Zidan JM, Karochero EY, Luder AS, Assy NN, et al. LDL oxidation is associated with increased blood hemoglobin A1c levels in diabetic patients. Clinica Chimica Acta. 2007;377:114–8.CrossRef
24.
Pennathur S, Heinecke JW. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antiox Redox Sig. 2007;9:955–69.CrossRef
25.
Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low-density-lipoprotein by a superoxide-dependent pathway. J Clin Invest. 1994;94:771–8.PubMedCrossRef
26.
Piga R, Naito Y, Kokura S, Handa O, Yoshikawa T. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis. 2007;193:328–34.PubMedCrossRef
27.
Dasu MR, Devaraj S, Jialal I. High glucose induces IL-1 beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab. 2007;293:E337–E46.PubMedCrossRef
28.
Cipolletta C, Ryan KE, Hanna EV, Trimble ER. Activation of peripheral blood CD14(+) monocytes occurs in diabetes. Diabetes. 2005;54:2779–86.PubMedCrossRef
29.
Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2006;69:36–45.PubMedCrossRef
30.
Rodriguez-Moran M, Guerrero-Romero F. Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. J Diabet Complicat. 1999;13:211–5.CrossRef
31.
Schena FP, Gesualdo L. Pathogenetic Mechanisms of Diabetic Nephropathy. J Am Soc Nephrol. 2005;16:S30–3.PubMedCrossRef
32.
Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32:219–26.PubMedCrossRef
33.
Long DA, Price KL, Herrera-Acosta J, Johnson RJ. How does angiotensin II cause renal injury? Hypertension. 2004;43:722–3.PubMedCrossRef
34.
Forbes JM, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes. 2007;115:69–84.PubMedCrossRef
35.
Kelly KJ, Wu P, Patterson CE, Temm C, Dominguez JH. LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes. Am J Physiol Renal Physiol. 2008;294:F1136–45.PubMedCrossRef
36.
Aoyama T, Fujiwara H, Masaki T, Sawamura T. Induction of lectin-like oxidized LDL receptor by oxidized LDL and lysophosphatidylcholine in cultred endothelial cell. J Mol Cell Cardiol. 1999;31:2101–14.PubMedCrossRef
37.
Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol. 2000;20:1116–22.PubMedCrossRef
38.
Marsche G, Levak-Frank S, Quehenberger O, Heller R, Sattler W, Malle E. Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells. FASEB J. 2001;15:1095–7.PubMed
39.
Oka K, Sawamura T, Kikuta K-i, Itokawa S, Kume N, Kita T, et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci USA. 1998;95:9535–40.PubMedCrossRef
40.
Honjo M, Nakamura K, Yamashiro K, Kiryu J, Tanihara H, McEvoy LM, et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci USA. 2003;100:1274–9.PubMedCrossRef
41.
Kakutani M, Masaki T, Sawamura T. A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. Proc Natl Acad Sci USA. 2000;97:360–4.PubMedCrossRef
42.
Shimaoka T, Kume N, Minami M, Hayashida K, Sawamura T, Kita T, et al. LOX-1 supports adhesion of Gram-positive and Gram-negative bacteria. J Immunol. 2001;166:1508–14.
43.
Murphy JE, Tacon D, Tedbury PR, Hadden JM, Knowling S, Sawamura T, et al. LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells. Biochem J. 2006;393:107–15.PubMedCrossRef
44.
Jonoab T, Miyazakia A, Nagaia R, Sawamurac T, Kitamurab T, Horiuchia S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett. 2002;511:170–4.CrossRef
45.
Murase T, Kume N, Korenaga R, Ando J, Sawamura T, Masaki T, et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83:328–33.PubMed
46.
Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res. 1999;84:1043–9.PubMed
47.
Hofnagel O, Luechtenborg B, Stolle K, Lorkowski S, Eschert H, Plenz G, et al. Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004;24:1789–95.PubMedCrossRef
48.
Nagase M, Ando K, Nagase T, Kaname S, Sawamura T, Fujita T. Redox-sensitive regulation of LOX-1 gene expression in vascular endothelium. Biochem Biophys Res Commun. 2001;281:720–5.PubMedCrossRef
49.
Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res. 2004;95:877–83.PubMedCrossRef
50.
Minami M, Kume N, Kataoka H, Morimoto M, Hayashida K, Sawamura T, et al. Transforming growth factor-beta (1) increases the expression of lectin-like oxidized low-density lipoprotein receptor-1. Biochem Biophys Res Commun. 2000;272:357–61.PubMedCrossRef
51.
Tan KCB, Shiu SWM, Wong Y, Leng L, Bucala R. Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus. J Lipid Res. 2008;49:1438–44.PubMedCrossRef
52.
Li L, Sawamura T, Renier G. Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res. 2004;94:892–901.PubMedCrossRef
53.
Navarra T, Turco SD, Berti S, Basta G. The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: catdiovascular inplications. J Atheroscler Thromb. 2010;17:317–31.PubMedCrossRef
54.
Kamezaki F, Yamashita K, Tasaki H, Kume N, Mitsuoka H, Kita T, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 correlates with oxidative stress markers in stable coronary artery disease. Int J Cardiol. 2009;134:285–7.PubMedCrossRef
55.
Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation. 2005;112:812–8.PubMedCrossRef
56.
Renier G, Maingrette F, Li L. Diabetic vasculopathy and the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). Curr Diabetes Rev. 2007;3:103–10.CrossRef
57.
Brinkley TE, Kume N, Mitsuoka H, Phares DA, Hagberg JM. Elevated soluble lectin-like oxidized LDL receptor 1 (LOX-1) levels in obese postmenopausal women. Obesity (Silver Spring). 2008;16:1454–6.CrossRef
58.
Kosaka H, Yoneyama H, Zhang L, Fujii S, Yamamoto A, Igarashi J. Induction of LOX-1 and iNOS expressions by ischemia-reperfusion of rat kidney and the opposing effect of L-arginine. FASEB J. 2003;17:636–43.PubMedCrossRef
59.
Bräsen JH, Nieminen-Kelhä M, Markmann D, Malle E, Schneider W, Neumayer HH, et al. Lectin-like oxidized low-density lipoprotein (LDL) receptor (LOX-1)-mediated pathway and vascular oxidative injury in older-age rat renal transplants. Kidney Int. 2005;67:1583–94.PubMedCrossRef
60.
Hyodo Y, Miyake H, Kondo Y, Fujisawa M. Downregulation of lectin-like oxidized low-density lipoprotein receptor-1 after ischemic preconditioning in ischemia-reperfused rat kidneys. Urology. 2009;73:906–10.PubMedCrossRef
61.
Hu C, Kang BY, Megyesi J, Kaushal GP, Safirstein RL, Mehta JL. Deletion of LOX-1 attenuates renal injury following angiotensin II infusion. Kidney Int. 2009;76:521–7.PubMedCrossRef
62.
Chen X, Zhang T, Du G. Advanced glycation end products serve as ligands for lectin-like oxidized low-density lipoprotein receptor-1(LOX-1): biochemical and binding characterizations assay. Cell Biochem Funct. 2008;26:760–70.PubMedCrossRef
63.
Jono T, Miyazaki A, Nagai R, Sawamura T, Kitamura T, Horiuchi S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett. 2002;511:170–4.PubMedCrossRef
64.
Iwashima Y, Eto M, Hata A, Kaku K, Horiuchi S, Ushikubi F, et al. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun. 2000;277:368–80.PubMedCrossRef
65.
Shiu SWM, Tan KCB, Wang Y, Leng L, Bucala R. Glycoxidized LDL increases lectin-like oxidized low density lipoprotein receptor-1 in diabetes mellitus. Atherosclerosis. 2009;203:522–7.PubMedCrossRef
66.
Taye A, Saad AH, Kumar AH, Morawietz H. Effect of apocynin on NADPH oxidase-mediated oxidative stress-LOX-1-eNOS pathway in human endothelial cells exposed to high glucose. Eur J Pharmacol. 2010;627:42–8.PubMedCrossRef
67.
Maingrette F, Renier G. Linoleic acid increases lectin-like oxidized LDL receptor-1 (LOX-1) expression in human aortic endothelial cells. Diabetes. 2005;54:1506–13.PubMedCrossRef
68.
Li D, Williams V, Liu L, Chen H, Sawamura T, Romeo F, et al. Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction. J Am Coll Cardiol. 2003;41:1048–55.PubMedCrossRef
69.
Hu C, Chen J, Dandapat A, Fujita Y, Inoue N, Kawase Y, et al. LOX-1 abrogation reduces myocardial ischemia-reperfusion injury in mice. J Mol Cell Cardiol. 2008;44:76–83.PubMedCrossRef
70.
Hu C, Dandapat A, Chen J, Fujita Y, Inoue N, Kawase Y, et al. LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion. Cardiovasc Res. 2007;76:292–302.PubMedCrossRef
71.
Andersson C, Gislason GH, Jørgensen CH, Hansen PR, Vaag A, Sørensen R. et al. Diabetes Res Clin Pract: Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure; 2011 Aug 8 [Epub ahead of print].
72.
Smirnova IV, Sawamura T, Goligorsky MS. Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in endothelial cells by nitric oxide deficiency. Am J Physiol Renal Physiol. 2004;287:F25–32.PubMedCrossRef
73.
Kelly KJ, Dominguez JH. Treatment of the post-ischaemic inflammatory syndrome of diabetic nephropathy. Nephrol Dial Transplant. 2010;25:3204–12.PubMedCrossRef
74.
Yamamoto N, Toyoda M, Abe M, Kobayashi T, Kobayashi K, Kato M, et al. Lectin-like oxidized LDL receptor-1 (LOX-1) expression in the tubulointerstitial area likely plays an important role in human diabetic nephropathy. Intern Med. 2009;48:189–94.PubMedCrossRef
75.
Zhang M, Gao X, Wu J, Liu D, Cai H, Fu L, et al. Oxidized high-density lipoprotein enhances inflammatory activity in rat mesangial cells. Diabetes Metab Res Rev. 2010;26:455–63.PubMedCrossRef
76.
Futrakul N, Futrakul P. Vascular homeostasis and angiogenesis determine therapeutic effectiveness in type 2 diabetes. Int J Vasc Med. Epub 2011 May 24.
77.
Dominguez JH, Mehta JL, Li D, Wu P, Kelly KJ, Packer CS, et al. Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations. Am J Physiol Renal Physiol. 2008;294:F110–9.PubMedCrossRef
78.
Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.PubMedCrossRef
79.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.PubMedCrossRef
80.
Li DY, Chen HJ, Mehta JL. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res. 2001;52:130–5.PubMedCrossRef
81.
Yu YH, Wang Y, Dong B, Sun SZ, Chen Y, Meng XH, et al. Fluvastatin prevents renal injury and expression of lectin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia. Chin Med J (Engl). 2005;118:621–6.
82.
Khaidakov M, Wang W, Khan JA, Kang BY, Hermonat PL, Mehta JL. Statins and angiogenesis: is it about connections? Biochem Biophys Res Commun. 2009;387:543–7.PubMedCrossRef
83.
Costa J, Borges M, David C, Vaz CA. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006;332:1115–24.PubMedCrossRef
84.
Mehta J, Hu B, Chen J, Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol. 2003;23:2203–8.PubMedCrossRef
85.
Chiba Y, Ogita T, Ando K, Fujita T. PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells. Biochem Biophys Res Commun. 2001;286:541–6.PubMedCrossRef
86.
Li L, Sawamura T, Renier G. Glucose enhances endothelial LOX-1 expression role for LOX-1 in glucose-induced human monocyte adhesion to endothelium. Diabetes. 2003;52:1843–50.PubMedCrossRef
87.
Wang L, Zhang L, Yu Y, Wang Y, Niu N. The protective effects of taurine against early renal injury in STZ-induced diabetic rats, correlated with inhibition of renal LOX-1-mediated ICAM-1 expression. Ren Fail. 2008;30:763–71.PubMedCrossRef
88.
Ouslimani N, Mahrouf M, Peynet J, Bonnefont-Rousselot D, Cosson C, Legrand A, et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism. 2007;56:308–13.PubMedCrossRef
89.
Li L, Renier G. The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells. Atherosclerosis. 2009;204:40–6.PubMedCrossRef
90.
Rudijanto A. Calcium channel blocker (diltiazem) inhibits apoptosis of vascular smooth muscle cell exposed to high glucose concentration through lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) pathway. Acta Med Indones. 2010;42:59–65.PubMed
91.
Yamagata K, Miyashita A, Chino M, Matsufuji H. Apigenin inhibits tumor necrosis factor alpha plus high glucose-induced LOX-1 expression in human endothelial cells. Microvasc Res. 2011;81:60–7.PubMedCrossRef
92.
Mehta JL, Chen J, Yu F, Li DY. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res. 2004;64:243–9.PubMedCrossRef
93.
Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293:1673–7.PubMedCrossRef
94.
Khaidakov M, Szwedo J, Mitra S, Ayyadevara S, Dobretsov M, Lu J, et al. Antiangiogenic and antimitotic effects of aspirin in hypoxia–reoxygenation modulation of the LOX-1-NADPH oxidase axis as a potential mechanism. J Cardiovasc Pharmacol. 2010;56:635–41.PubMedCrossRef
Metadaten
Titel
LOX-1, Oxidative Stress and Inflammation: A Novel Mechanism for Diabetic Cardiovascular Complications
verfasst von
Meiling Yan
Jawahar L. Mehta
Weifang Zhang
Changping Hu
Publikationsdatum
01.10.2011
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 5/2011
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-011-6342-4

Weitere Artikel der Ausgabe 5/2011

Cardiovascular Drugs and Therapy 5/2011 Zur Ausgabe

OriginalPaper

The Discovery of LOX-1, its Ligands and Clinical Significance

OriginalPaper

Oxidized LDL, LOX-1 and Atherosclerosis

OriginalPaper

LOX-1: A New Target for Therapy for Cardiovascular Diseases

OriginalPaper

Novel Concepts in the Genesis of Hypertension: Role of LOX-1

Review Article

LOX-1 Transcription

OriginalPaper

Oxidized Low Density Lipoproteins-Do We Know Enough About Them?

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen